Welcome to our dedicated page for Waldencast plc news (Ticker: WALD), a resource for investors and traders seeking the latest updates and insights on Waldencast plc stock.
Waldencast plc (NASDAQ: WALD) is a global multi-brand beauty and wellness platform built around the Obagi Medical and Milk Makeup brands. Its news flow centers on segment performance, brand initiatives, and platform-level strategic decisions, providing investors and observers with regular insight into how the company executes its brand-led strategy.
Company updates frequently include quarterly and half-year financial results, furnished to the U.S. Securities and Exchange Commission on Form 6-K and summarized in detailed press releases. These communications break out net revenue, adjusted gross profit, and adjusted EBITDA for Waldencast as a whole and for the Obagi Medical and Milk Makeup segments, highlighting trends across channels and geographies as described by the company.
News related to Obagi Medical often covers product and portfolio developments, clinical data, and expansion into aesthetics. Examples include announcements about FDA approval of Obagi-branded hyaluronic acid injectable products, new clinical data on Obagi hyaluronic acid injectables and scalp serum at professional dermatology meetings, and the acquisition of Novaestiq Corp. and U.S. rights to the Saypha injectable line. These items illustrate how Waldencast presents Obagi Medical’s role at the intersection of skincare and medical aesthetics.
Updates about Milk Makeup focus on brand performance in prestige beauty and digital channels, including references to U.S. retail sales trends, expansion into retailers such as Ulta Beauty and Amazon Premium Beauty, and the impact of specific product launches as described in the company’s quarterly commentary.
At the corporate level, Waldencast’s news also addresses strategic reviews and financing actions, such as the announced review of strategic alternatives by the Board of Directors, the sale of the “Obagi” trademark in Japan, and new credit agreements. Readers of the WALD news page can expect a mix of earnings updates, brand-specific developments, clinical and regulatory milestones, and capital structure announcements directly sourced from company press releases and related SEC filings.
Waldencast plc (NASDAQ: WALD) reported Q3 2022 net sales of $78.9 million with a gross margin of 62.4% and an adjusted gross margin of 71.9%. Despite these positive metrics, the company faced a net loss of $16.8 million. Adjusted EBITDA stood at $15.3 million, accounting for 19.4% of net sales. The management reaffirmed its fiscal 2022 guidance, projecting net sales of $256.3 million alongside a gross profit of $189.8 million and adjusted EBITDA of $49.6 million. Waldencast highlighted its robust brand performance and strong growth prospects in a challenging macroeconomic environment.
Waldencast plc (NASDAQ: WALD) is set to discuss its Q3 2022 earnings results on a conference call scheduled for November 10, 2022, at 8:30 AM ET. The earnings press release will be available before the call. Investors can join via phone or access a live webcast through their investor relations page. Waldencast aims to build a leading beauty and wellness platform by developing and scaling high-growth brands, benefiting from operational scale and market responsiveness.
Waldencast plc (NASDAQ: WALD) announced the appointment of Philippe Gautier as Chief Financial Officer and Chief Operating Officer, effective October 19, 2022. Gautier brings over 30 years of experience from leading global consumer companies, most recently as Group CFO at Selecta. His track record includes significant roles at Kering, managing luxury brands. CEO Michel Brousset expressed confidence that Gautier's expertise will enhance Waldencast's strategic goals in building a world-class beauty and wellness brand portfolio. The company aims to develop, acquire, and scale high-growth brands in this sector.
Waldencast plc (NASDAQ: WALD) will participate in the Raymond James 2022 Consumer Conference in New York on September 15, 2022, where CEO Michel Brousset will engage in a fireside chat. The session will be available for live viewing and replay on the company's Investor Relations page. Waldencast aims to build a leading beauty and wellness platform by developing and scaling purpose-driven brands, with its initial focus on Obagi Skincare and Milk Makeup. The company emphasizes agility and close customer connections, ensuring each brand retains its unique identity.
Waldencast plc (NASDAQ: WALD) reported strong financial performance for the second quarter and first half of 2022. Total net sales reached $138.2 million, a 24.6% increase from the previous year. Q2 net sales were $77.1 million, up 23.8%. The gross margin improved to 75.1%, a rise of 578 basis points. Pro Forma Adjusted EBITDA was $21.9 million in Q2, marking a 38.6% increase. Waldencast reaffirmed its guidance for fiscal 2022, anticipating net sales of $256.3 million.
Waldencast plc (NASDAQ: WALD), a beauty and wellness platform, has scheduled a conference call on August 11, 2022, at 8:00 AM ET to discuss its second quarter and first half 2022 earnings results. The earnings press release will be available before the call. Interested investors can join by dialing (855) 327-6837 or (631) 891-4304 for international participants. The call will be webcast live and accessible for 90 days post-event. Waldencast aims to build a best-in-class beauty platform through strategic brand management and operational efficiencies.
Waldencast plc has officially begun trading on the Nasdaq under the ticker symbol WALD, after completing a merger with Obagi Skincare and Milk Makeup on July 27, 2022. The combined entity aims to create a leading beauty and wellness platform focused on developing purpose-driven brands. CEO Michel Brousset emphasized the company's commitment to empowering brands like Obagi and Milk Makeup. The leadership will remain intact for both skincare brands, with each dedicated to enhancing their market presence while aligning with Waldencast's vision for operational excellence.
Waldencast plc has announced the completion of its merger with Obagi Skincare and Milk Makeup, set to trade on Nasdaq under the ticker symbol WALD beginning July 28, 2022. The company aims to create a leading beauty and wellness platform, enhancing the growth of its brands through operational support while preserving their unique identities. CEO Michel Brousset emphasized the merger as a pivotal step towards building a conscious brand portfolio, while Executive Chairman Felipe Dutra expressed confidence in the group's capabilities to navigate the beauty market.
Waldencast Acquisition Corp. (NASDAQ: WALD) announced that its shareholders overwhelmingly approved the business combination with Obagi Skincare and Milk Makeup, with approximately 98% support. The merger is expected to close around July 27, 2022, pending all closing conditions. Post-merger, the combined entity will be named Waldencast plc and trade under the ticker 'WALD' on Nasdaq. This merger marks a strategic move for Waldencast to establish a multi-brand beauty platform, integrating well-known skin and makeup brands.
Waldencast Acquisition Corp. (NASDAQ: WALD) has announced an extraordinary general meeting for its shareholders on July 25, 2022, to vote on the proposed business combination with Obagi Skincare and Milk Makeup. The SEC has declared effective the registration statement related to this deal. If approved, the merger will position the combined entity on Nasdaq under the symbol WALD. Shareholders are encouraged to vote 'FOR' all proposals and to review the definitive proxy statement thoroughly before the meeting.